Author pages are created from data sourced from our academic publisher partnerships and public sources.
An Intramembrane Modulator of the ErbB2 Receptor Tyrosine Kinase That Potentiates Neuregulin Signaling*
- K. Carraway, E. A. Rossi, +6 authors C. A. Carraway
- Medicine, Biology
- The Journal of Biological Chemistry
- 26 February 1999
The ErbB2 receptor tyrosine kinase plays a critical role in a variety of developmental processes, and its aberrant activation may contribute to the progression of some breast and ovarian tumors.… Expand
Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab.
- E. A. Rossi, D. Goldenberg, R. Michel, Diane L. Rossi, D. Wallace, Chien-Hsing Chang
- 24 October 2013
Epratuzumab, a humanized anti-CD22 antibody, is currently in clinical trials of B-cell lymphomas and autoimmune diseases, demonstrating therapeutic activity in non-Hodgkin lymphoma (NHL) and systemic… Expand
Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody.
Veltuzumab is a humanized anti-CD20 monoclonal antibody with complementarity-determining regions (CDRs) identical to rituximab, except for one residue at the 101st position (Kabat numbering) in CDR3… Expand
Development of an imaging-guided CEA-pretargeted radionuclide treatment of advanced colorectal cancer: first clinical results
Background:Radiolabelled antibody targeting of cancer is limited by slow blood clearance. Pretargeting with a non-radiolabelled bispecific monoclonal antibody (bsMAb) followed by a rapidly clearing… Expand
Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas.
We describe the use of novel bispecific hexavalent Abs (HexAbs) to enhance anticancer immunotherapy. Two bispecific HexAbs [IgG-(Fab)(4) constructed from veltuzumab (anti-CD20 IgG) and milatuzumab… Expand
Improving the therapeutic index in cancer therapy by using antibody-drug conjugates designed with a moderately cytotoxic drug.
The antibody-drug conjugate (ADC), IMMU-130, of the moderately cytotoxic topoisomerase I inhibitor, SN-38, and the CEACAM5-targeted humanized antibody (mAb), labetuzumab, was evaluated in model… Expand
Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting.
- E. A. Rossi, D. Goldenberg, T. Cardillo, W. McBride, R. Sharkey, Chien-Hsing Chang
- Medicine, Biology
- Proceedings of the National Academy of Sciences…
- 2 May 2006
We describe a platform technology, termed the dock and lock method, which uses a natural binding between the regulatory subunits of cAMP-dependent protein kinase and the anchoring domains of A kinase… Expand
Multifunctional Antibodies by the Dock-and-Lock Method for Improved Cancer Imaging and Therapy by Pretargeting
- D. Goldenberg, E. A. Rossi, R. Sharkey, W. McBride, Chien-Hsing Chang
- Chemistry, Medicine
- Journal of Nuclear Medicine
- 12 December 2007
The Dock-and-Lock (DNL) method, which makes bioactive molecules with multivalency and multifunctionality, is a new approach to develop targeting molecules for improved cancer imaging and therapy. It… Expand
Improved 18F labeling of peptides with a fluoride-aluminum-chelate complex.
- W. McBride, Christopher A. D'souza, +4 authors D. Goldenberg
- Medicine, Chemistry
- Bioconjugate chemistry
- 14 June 2010
We reported previously the feasibility to radiolabel peptides with fluorine-18 ((18)F) using a rapid one-pot method that first mixes (18)F(-) with Al(3+) and then binds the (Al(18)F)(2+) complex to a… Expand
CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas.
Interferon-alpha (IFN-alpha) has direct inhibitory effects on some tumors and is a potent stimulator of both the innate and adaptive immune systems. A tumor-targeting antibody-IFN-alpha conjugate… Expand